New agonist- and antagonist-based treatment approaches for advanced prostate cancer.

about

AntiAngioPred: A Server for Prediction of Anti-Angiogenic Peptides Advances in androgen receptor targeted therapy for prostate cancer Bombesin related peptides/receptors and their promising therapeutic roles in cancer imaging, targeting and treatment.

P2860

Q35763338-14B1C262-09F7-4E46-A42F-D532D1799710 Q37337217-5052398B-68F6-4975-9CB8-5AAB7B73BF8A Q38776596-6E3D39D0-CDD8-4456-A1F9-F9C1AE0EC15B

P2860

New agonist- and antagonist-based treatment approaches for advanced prostate cancer.

Item

http://www.wikidata.org/entity/Q38042768

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

New agonist- and antagonist-based treatment approaches for advanced prostate cancer.

@en

type

Item

label

New agonist- and antagonist-based treatment approaches for advanced prostate cancer.

@en

prefLabel

New agonist- and antagonist-based treatment approaches for advanced prostate cancer.

@en

P1476

New agonist- and antagonist-based treatment approaches for advanced prostate cancer.

@en

P2093

B Wu

http://www.w3.org/2001/XMLSchema#string

Y F Jiang

http://www.w3.org/2001/XMLSchema#string

Y Xu

http://www.w3.org/2001/XMLSchema#string

P2860

Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists

Cancer statistics, 2009

Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study.

Role of bombesin-related peptides in the control of food intake.

Neuroendocrine cells in tumour growth of the prostate.

Antagonist of growth hormone-releasing hormone induces apoptosis in LNCaP human prostate cancer cells through a Ca2+-dependent pathway.

Peptide analogs in the therapy of prostate cancer.

Molecular genetics of prostate cancer: new prospects for old challenges

The current state of hormonal therapy for prostate cancer.

Expression of growth hormone-releasing hormone (GHRH) and splice variants of GHRH receptors in human experimental prostate cancers.

P304

1217-1226

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/147323001204000401

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230841143

http://www.w3.org/2001/XMLSchema#string

P698

22971474

http://www.w3.org/2001/XMLSchema#string

New agonist- and antagonist-based treatment approaches for advanced prostate cancer.

about

P2860

P2860

New agonist- and antagonist-based treatment approaches for advanced prostate cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698